173
Views
5
CrossRef citations to date
0
Altmetric
Review

Nasal and pulmonary drug delivery systems

, &
Pages 315-323 | Published online: 25 Feb 2005

Bibliography

  • DAVIS SS: Delivery of peptide and non-peptide drugs through the respiratory tract. Pharm. Sci. Technol. Today (1999) 2:450–456.
  • •Review on recent advances in the delivery of both peptide and non-peptide drugs to the respiratory tract. A comparison between nasal and pulmonary delivery is made.
  • BEHL CR, PIMPLASKAR HK, SILENO AP, DEMEIRELES J, ROMEO VD: Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev. (1998) 29:89–116.
  • ••Review on the feasibility evaluation of drug nasal deliveryfrom anatomical considerations to preformulation studies leading to the development of a final formulation.
  • BOMMER R: Advances in nasal drug delivery technology. Pharm. Technol Eur. (1999):26–33.
  • •Review on some of the latest devices for liquid and dry powder formulations including preservative-free systems.
  • BATTS AH, MARRIOTT C, MARTIN GP, BOND SW: The effect of some preservatives used in nasal prepara-tions on mucociliary clearance. J. Pharm. Pharmacol (1989) 41:156–159.
  • •This reference describes the effects of some preservatives used in multi-dose nasal preparations on mucociliary transport rate.
  • ILLUM L: Drug delivery systems for nasal application. STP Pharma. (1987) 3:594–598
  • •General description of the delivery systems suitable for intranasal administration of drugs.
  • BEHL CR, PIMPLASKAR HK, SILENO AP et al.: Optimiza- tion of systemic nasal drug delivery with pharmaceu-tical excipients. Adv. Drug Deliv. Rev. (1998) 29:117–133.
  • ••This review discusses the most widely used formulationapproaches to improve drug absorption through the nasal administration route.
  • DUCHENE D, TOUCHARD F, PEPPAS NA: Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Devel. Indust. Pharm. (1988) 14:283–318.
  • •This paper deeply investigates bioadhesion mechanisms, factors influencing bioadhesion phenomema, bioadhesive polymers and dosage forms.
  • PERESWETOFF-MORATH L: Microspheres as nasal drug delivery systems. Adv. DrugDeliv. Rev. (1998) 29:185–194.
  • •Review on different types of microspheres that can be used to improve nasal absorption of drugs. Microspheres made of different materials are compared for their in vivo behavior as drug delivery also considering toxicological aspects.
  • DE PONTI R, LARDINI E: Use of chemical enhancers for nasal delivery. Drug Dev. Ind. Pharm. (1991) 17(10:1419–1436.
  • •This paper gives a general and widespread overview on chemical enhancers considered for nasal drug delivery.
  • KOTZÉ AF, LUESSEN HL, DE BOER AG, VERHOEF JC, JUNGINGER HE: Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur. J. Pharm. Sci. (1998) 7:145–151.
  • •This reference offers a deep experimental evaluation of chitosan as a mucoadhesive polymer suitable to be used to enhance trough transmucosal drug absorption.
  • MEGGS WJ: Mechanism of allergy and chemical sensitivity. Toxicol. Ind. Health (1999) 15(3-4):331–338.
  • •This paper describes allergy and chemical sensitivity mechanism.
  • SUONPAA J: Treatment of allergic rhinitis. Ann. Med. (1996) 28(0:17–22.
  • •The reference describes therapeutic strategies to treat allergic rhinitis.
  • KRAUSE HF: Pharmacotherapy of perennial and seasonal allergic rhinitis. Clin. Immunother. (1995) 3 (4):308–324.
  • •The reference describes therapeutic strategies to treat allergic rhinitis by the use of anti-histamines, corticosteroids, decongestants, mast cell stabilisers and other agents, such as mucolytics and anticholinergics.
  • LAVELLE E: Targeted mucosal delivery of drugs and vaccines. Exp. Opin. Ther. Patents (2000) 10 (2):179–190.
  • •This review examines the potential for targeted mucosal drug and vaccine delivery.
  • JENKINS PG: Mucosal vaccine delivery. Exp. Opin. Ther. Patents (1999) 9(3):255–262.
  • •This reference offers a description of the recent advances on drug delivery strategies for mucosal administration of vaccines. Strengths and weaknesses of different approaches are discussed.
  • McCLUSKIE MJ, DAVIS HL: Novel strategies using DNA for the induction of mucosal immunity. Grit. Rev. Immunol. (1999) 19 (4) :303–329.
  • •This paper describes the recent advances in vaccination strategies using DNA delivered to mucosal surfaces.
  • CORNAZ AL, BURI P: Nasal mucosa as an absorption barrier. Eur. J. Pharm. Biopharm. (1994) 40(5) :261–270.
  • •This paper provides a detailed description of the nasal mucosal barrier: a good comprehension of the factors limiting drug permeation trough nasal mucosa can lead to the identification of effective strategies to improve intranasal absorption of drugs.
  • MERKUS FWHM, VERHOEF JC, MARTTIN E et al.: Cyclodextrins in nasal drug delivery. Adv. Drug Deliv. Rev. (1999) 36:41–57.
  • •In the review the use of cyclodextrins in nasal drug formula-tion both as solubilising agents and absorption enhancers is discussed. It is an example of a new class of safe enhancers. A special focus is given to intranasal protein and peptide intranasal formulation.
  • MARINARO M, DI TOMASO A, UZZAU S, FASANO A, DE MAGISTRIS MT: Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect. Immun. (1999) 67 (3) :1287–1291.
  • •This reference focuses on the possibility the use Zonula occludens toxin (ZOT) as an adjuvant to deliver soluble antigens through the nasal mucosa.
  • NEWMAN SP: Optimizing delivery of drugs to the lungs. Clin. Asthma Rev. (1998) 2:123–128.
  • •Review of current trends of optimising delivery devices for the effective treatment of asthma.
  • Inhalation Aerosols. Hickey AJ (Ed.), Marcel Dekker, Inc., New York, USA (1996).
  • ••This reference combines the physical chemistry of formula-tion with the physics of aerosol generation and aerodynamic behavior in order to better understand their therapeutic implications for inhalation aerosols.
  • YU J, CHIEN YW: Pulmonary drug delivery: physiologic and mechanistic aspects. Grit. Rev. Ther. Drug Carrier Syst. (1997) 14(4):395–453.
  • •Presentation of numerous case studies for the pulmonary delivery of proteins and peptides.
  • Inhalation Delivery of Therapeutic Proteins and Peptides. Adjei LA, Gupta PK (Eds.), Marcel Dekker, Inc., New York, USA (1997).
  • ••This reference offers a comprehensive analysis of proteinand peptide delivery through the lung including a detailed description of the human respiratory tract and its impact on both local and systemic delivery of biotherapeutic and macromolecular drug systems.
  • ROSS DL, GABRIO BJ: Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug carrier system. J. Aerosol Med. (1999) 12(3):151–160.
  • •Article presents formulation implications observed in CFC-free pMDIs.
  • KELLER M: Developments and trends in pulmonary drug delivery. Chimica Oggi (1998) 16: (11/12) :16–24.
  • •Review of inhalation drug delivery and of the importance of its understanding for effectively dealing with pulmonary functions and diseases.
  • MOBLEY JL, CHIN JE, RICHARDS IM: Glucocorticoster- oids, old and new: biological function and use in the treatment of asthma. Exp. Opin. Invest. Drugs (1996) 5 (7) :871–884.
  • •Expert opinion on old and new glucocorticosteroids used in the treatment of asthma.
  • PATTON JS, BUKAR J, NAGARAJAN S: Inhaled insulin. Adv. Drug Deliv. Rev. (1999) 35 (2,3):235–247.
  • •A review of clinical observations from inhaled insulin studies.
  • WU-PONG S, BYRON PR: Airway-to-biophase transfer of inhaled oligonucleotides. Adv. Drug Delivery Rev. (1996) 19(1):47–71.
  • •A review of oligonucleotide delivery to and uptake by the lung. While systemic delivery remains problematical, topical delivery appears reasonable.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.